Kalaris Therapeutics (KLRS) CFO named as reporting person on Form 3
Rhea-AI Filing Summary
Kalaris Therapeutics, Inc. lists Liisa Ann Bayko, its Chief Financial Officer, as a reporting person on Form 3. The Form 3 data show no equity holdings, derivative positions, or buy or sell transactions currently reported for her in Kalaris Therapeutics securities.
Positive
- None.
Negative
- None.
Key Figures
Reported buy transactions: 0
Reported sell transactions: 0
Holding entries: 0
3 metrics
Reported buy transactions
0
Buy transactions (buyCount) in the Form 3 transactionSummary
Reported sell transactions
0
Sell transactions (sellCount) in the Form 3 transactionSummary
Holding entries
0
Non-derivative holdingEntries reported in the Form 3 data
Key Terms
Power of Attorney, Chief Financial Officer, Form 3
3 terms
Power of Attorney regulatory
"Remarks state: Exhibit 24.1 - Power of Attorney"
A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.
Chief Financial Officer financial
"Reporting person is listed with officer_title "Chief Financial Officer""
A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.
Form 3 regulatory
"Filing type is identified as Form 3 for insider reporting"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Kalaris Therapeutics (KLRS) report about Liisa Ann Bayko in this Form 3?
Kalaris Therapeutics reports that Liisa Ann Bayko is a reporting person on Form 3 and serves as Chief Financial Officer. The Form 3 data show no listed equity holdings, derivative positions, or buy or sell transactions in Kalaris Therapeutics securities for her.
Are any buy or sell transactions reported for KLRS in Liisa Ann Bayko's Form 3?
No buy or sell transactions are reported; all buyCount and sellCount values are zero in the transaction summary. The Form 3 transaction list is empty, indicating no trades in Kalaris Therapeutics securities are disclosed for this reporting person.
Does the Kalaris Therapeutics (KLRS) Form 3 show any current equity holdings for Liisa Ann Bayko?
No equity holdings are shown; the Form 3 data indicate holdingEntries = 0. Together with an empty derivative summary, this means no non-derivative or derivative positions in Kalaris Therapeutics securities are reported for Liisa Ann Bayko in this Form 3.
Are any derivative securities reported for Liisa Ann Bayko in the KLRS Form 3?
No derivative securities are reported; the derivativeSummary is empty and derivativeTransactionCount is zero. This indicates no options, warrants, or other derivative positions in Kalaris Therapeutics securities are disclosed for her in this Form 3 data.
What is Liisa Ann Bayko's role at Kalaris Therapeutics (KLRS) according to the Form 3 data?
According to the Form 3 data, Liisa Ann Bayko is an officer of Kalaris Therapeutics serving as Chief Financial Officer. She is identified as a reporting person, while director and ten percent owner indicators are not marked for her in this dataset.